Market Analysis: Global Pemphigoid Drug Market

Pemphigoid drug market to grow at a substantial CAGR in the forecast period of 2019-2026. Growing pemphigoid population and exposure to certain toxin or change in environment may increase the pemphigoid disease are the key drivers for market growth.

Market Definition: Global Pemphigoid Drug Market

Pemphigoid is a rare autoimmune skin disorder that causes the body’s own immune system to attack the layer of skin and separates the bottom layer of skin from above layers, resulting in blistering, itching, redness and rashes. This disease mostly develops in geriatric population.

According to statistics published in European Medicines Agency, 2.5 in every 10,000 people were diagnosed with bullous pemphigoid in the European Union in the year of 2018. This growing incidence of pemphigoid disease, vulnerable aging population and accelerating the demand of newer therapies are key factors for rise in market growth.

Get More Insights About Global Pemphigoid Drug Market, Request Sample @

Market Drivers

  • Increase in prevalence rate of pemphigoid disease worldwide
  • Exposure to certain toxin or change in environment may increase the pemphigoid disease
  • Rising awareness about treatment and technological advancement is driving the growth of market
  • Rapid adoption of newer formulations and novel dosage forms

Market Restraints

  • Effective treatment is either unavailable or unaffordable
  • Patent expiry from many companies and introduction of generic drugs of branded version is expected to restrain the growth if the market
  • Inadequate knowledge about pemphigoid in some developing countries

Segmentation: Global Pemphigoid Drug Market

By Type

  • Bullous Pemphigoid
  • Cicatricial Pemphigoid
  • Pemphigoid Gestationis

By Medication Type

  • Corticosteroids
    • Prednisone
    • Clobetasol propionate
  • Anti-biotics
    • Doxycycline
  • Steroid-sparing immunosuppressant drugs
    • Azathioprine
    • Mycophenolate mofetil
  • Others

By Route of administration

  • Oral
  • Injectable
  • Topical

By Distribution Channel

  • Online Pharmacy
  • Direct Tenders
  • Retailers
  • Others

By End Users

  • Hospitals
  • Homecare
  • Specialty Clinics
  • Others

By Geography

  • North America
    • U.S.
    • Canada
    • Mexico
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Russia
    • Turkey
    • Belgium
    • Netherlands
    • Switzerland
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • South Korea
    • India
    • Australia
    • Singapore
    • Thailand
    • Malaysia
    • Indonesia
    • Philippines
    • Rest of Asia Pacific
  • Middle East & Africa
    • South Africa
    • Egypt
    • Saudi Arabia
    • United Arab Emirates
    • Israel
    • Rest of Middle East & Africa

Know more about this report

Key Developments in the Market:

In April 2019, Akari Therapeutics, Plc reported the Phase II trial results where the trial demonstrated well toleration of Nomacopan (Coversin), given subcutaneously in three elderly patients (>65 years) for the treatment of bullous pemphigoid. If approved it will shift from the conventional therapies to novel disease specific treatment for the patients suffering from pemphigoid.

In August 2018, Immune Pharmaceuticals, Inc received Orphan Drug designation from the US FDA for Bertilimumab for the treatment of bullous pemphigoid. If approved, it will be the potential commercial milestone for Immune Pharmaceuticals, Inc

Competitive Analysis:

Global pemphigoid drug market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of Pemphigoid Drug market for global, Europe, North America, Asia-Pacific, South America and Middle East & Africa.

Get Access Report @

Key Market Players:

Few of the major competitors currently working in the global pemphigoid drug market are Novartis AG, Takeda Pharmaceutical Company Limited, TWi Pharmaceuticals, Inc, Immune Pharmaceuticals, Inc., Dompé farmaceutici S.p.A., Eli Lilly and Company, F. Hoffmann-La Roche Ltd, Sanofi, Akari Therapeutics, Plc, Johnson & Johnson Services, Inc , AbbVie Inc, Amgen Inc , Celgene Corporation, Bausch Health, Bristol-Myers Squibb Company, Merck & Co. Inc., GlaxoSmithKline plc, Mylan N.V., Merz Pharma and many others.

Primary Respondents

Demand Side: Doctors, Surgeons, Medical Consultants, Nurses, Hospital Buyers, Group Purchasing Organizations, Associations, Insurers, Medical Payers, Healthcare Authorities, Universities, Technological Writers, Scientists, Promoters, and Investors among others.

Supply Side: Product Managers, Marketing Managers, C-Level Executives, Distributors, Market Intelligence, and Regulatory Affairs Managers among others.

Request for Detailed TOC @

Browse Trending Related Reports @

About Data Bridge Market Research:

Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market


Data Bridge Market Research

Tel: +1-888-387-2818

Email: [email protected]